GSK PLC GSK shares shed 2.40% to £13.41 Wednesday, on what proved to be an all-around positive trading session for the stock ...
GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...
GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.
Based on DREAMM-7 and another positive phase 3 trial, DREAMM-8 for Blenrep’s combination with Bristol Myers Squibb’s Pomalyst ...
Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...
Shares of GSK PLC GSK inched down 0.69% to £13.74 Tuesday, on what proved to be an all-around poor trading session for the ...
GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...
As part of the deal, GSK will pay Relation $45 million in upfront payments, which includes an equity investment of $15 million.
Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback